Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Accumulated Expenses (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Accumulated Expenses for 6 consecutive years, with $4.1 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses fell 38.46% to $4.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.1 million through Dec 2025, down 38.46% year-over-year, with the annual reading at $4.1 million for FY2025, 38.46% down from the prior year.
  • Accumulated Expenses for Q4 2025 was $4.1 million at TScan Therapeutics, down from $5.8 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $7.1 million in Q2 2025, with the low at $1.3 million in Q2 2022.
  • Average Accumulated Expenses over 5 years is $4.2 million, with a median of $4.1 million recorded in 2025.
  • Peak annual rise in Accumulated Expenses hit 259.52% in 2022, while the deepest fall reached 66.09% in 2022.
  • Over 5 years, Accumulated Expenses stood at $1.9 million in 2021, then soared by 259.52% to $6.8 million in 2022, then dropped by 19.89% to $5.5 million in 2023, then increased by 22.95% to $6.7 million in 2024, then tumbled by 38.46% to $4.1 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $4.1 million, $5.8 million, and $7.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.